PODD News and Press, Insulet Corporation From 03/23/25

2025-03-23 09:05:46 ET Pfizer exits Haleon stake after $3.2B share sale More on Health Care Select Sector SPDR® Fund ETF XLV: With Relative Strength In January And Compelling Valuation, Health Care Earnings On Tap XLV: Buy Diversity And Growth SA Charts:...

2025-03-21 08:30:00 ET Summary Global equities fell in Q4, specifically in December, as the Federal Reserve signaled that it is unlikely to cut rates in 2025 as sharply as markets had anticipated. The Artisan International Small-Mid Fund  portfolio outperformed the MSCI ACWI ...

2025-03-19 16:43:29 ET More on Insulet Insulet Leans Bullish (Technical Analysis) Insulet: Aiding Patients And Investors Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript Insulet announces pricing of senior notes due 2033 Insulet announces p...

First randomized controlled trial to evaluate direct transition from multiple daily injections to automated insulin delivery in adults and children with type 1 diabetes who were not meeting glycemic targets with injections People using Omnipod 5 had significantly improved HbA1c levels (av...

2025-03-18 16:47:31 ET More on Insulet Insulet Leans Bullish (Technical Analysis) Insulet: Aiding Patients And Investors Insulet targets 16%-20% U.S. Omnipod growth for 2025 with expanded type 2 diabetes market reach Read the full article on Seeking Alpha ...

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, has priced a private placement of $450 million aggregate principal amount of senior unsecured notes due...

2025-03-18 07:47:20 ET More on Insulet Insulet Leans Bullish (Technical Analysis) Insulet: Aiding Patients And Investors Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript Insulet targets 16%-20% U.S. Omnipod growth for 2025 with expanded type 2 diab...

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its intention to offer, subject to market and other conditions, $450 million aggregate ...

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland. Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod &#x...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the Company will present results from its multinational Randomized Controlled Trial to Demonstrate the Efficacy of ...